Drug Trial Radar · NCT06856772
Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial
Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
42,000
Planned (sponsor's estimate)
Start
Feb 28, 2025
Primary completion
Mar 28, 2028
Study completion Mar 28, 2028
Sponsor
- Lead sponsor
- Tor Biering-SørensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Herlev and Gentofte Hospital
- First posted
- Mar 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Statins inhibit hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyzes the rate-limiting step in cholesterol synthesis. This in turn leads to reductions in concentrations of low-density lipoprotein (LDL) cholesterol and C-reactive protein which reduces the risk of incident atherosclerotic events among individuals both with and without a history of atherosclerotic cardiovascular Several pilot studies have suggested potential benefits of taking statin in the evening rather than in the morning. The primary objective of this study is to examine whether statin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking statin.
Conditions
- Cardiovascular Diseases (CVD)
- Drug Effect
- Atherosclerosis Cardiovascular Disease
Interventions
Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)Drug
Participants will be instructed to take their Statin daily at approx. 8PM-12AM.
Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)Drug
Participants will be instructed to take their statin upon awakening/or with their breakfast (approx. 6AM-10AM).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of hospitalization for myocardial infarction, hospitalization for stroke or cardiovascular deathTime frame: Will be assessed in a time-to-first-event approach from date of randomization until end of study (up til 5 years).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
Hellerup, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.